Healthcare  |  Drug Manufacturers—General
277.66 1.49 0.54%
Stock Price | Aug. 6, 2020, 4 p.m.
Bid: 0.0
Ask: 0.0
Prev. Close: 276.17
52 Week Low: 215.775
52 Week High: 374.99
PE Ratio: 8.113102
Dividend Yield: 0.0%

Company Summary

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Read more Read less

Recently Viewed Tickers

Free Stocks With Near-Term Upside Potential

4 years ago